Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 9Neoplasms 6Ovarian Neoplasms 4Colorectal Neoplasms 4Prostatic Neoplasms 3Carcinoma, Hepatocellular 3Peritoneal Neoplasms 2Mesothelioma 1Malignant Solid Tumour 1Genital Neoplasms, Female 1Carcinoma, Renal Cell 1

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × nintedanib × Clear all
NCT01004003 2017-10-26

Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Boehringer Ingelheim

Phase 2 Completed
125 enrolled 19 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT00987935 2016-03-10

A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

Boehringer Ingelheim

Phase 2 Completed
134 enrolled 29 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01594125 2016-02-12

Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

Boehringer Ingelheim

Phase 1 Completed
30 enrolled 12 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡